Video

Redefining CGTs With Exosomes And EVs | Audience Q&A

Source: Cell & Gene

The audience Q&A session covered a wide range of practical and scientific challenges in developing extracellular vesicle (EV)-based therapeutics. Aegle Therapeutics’ CMO, Dr. Gloria Matthews, emphasized the critical role of CDMOs in early development, especially for small biotechs without in-house capabilities. Dosing remains an open question. Release criteria, potency assays, and more were also covered in this segment. 

access the Video!

Get unlimited access to:
Trend and Thought Leadership Articles
Case Studies & White Papers
Extensive Product Database
Members-Only Premium Content
Welcome Back! Please Log In to Continue. X

Enter your credentials below to log in. Not yet a member of Cell & Gene? Subscribe today.

Subscribe to Cell & Gene X

Please enter your email address and create a password to access the full content, Or log in to your account to continue.

or

Subscribe to Cell & Gene

Please tell us more about you so that we can customize our newsletters to your specific interests:

What topics interest you? (Check all that apply.)